Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 43

Sort by

Sort Order Select

Journal Articles

Ponatinib Treatment in CML and Ph+ ALL Patients: Real-Life Data from the Czech Registries

Eva Koriťáková, RNDr., PhD, Michael Doubek, MD PhD, Edgar Faber, MD PhD, Daniela Žáčková, MD PhD, Jan M. Horáček, MD PhD, Petra Bělohlávková, MD PhD, Eduard Cmunt, MD PhD, František Folber, MD PhD, Pavel Jindra, MD PhD, Hana Klamová, MD PhD, Zdeněk Kořístek, MD PhD, Lukáš Stejskal, MD, Tomáš Szotkowski, MD PhD, Cyril Šálek, MD PhD, Renata Kellnerová, MD PhD, Marika Chrápavá, Mgr.

Blood (2019) 134 (Supplement_1): 5905.

https://doi.org/10.1182/blood-2019-126395

Published: 2019

Journal Articles

Preliminary Results of CML1214, a Survey on Ponatinib Compassionate Use in Italy By the Gimema CML Working Party

Blood (2019) 134 (Supplement_1): 2931.

https://doi.org/10.1182/blood-2019-125052

Published: 2019

Journal Articles

Outcomes and Side Effect Profile of Ponatinib in Treatment of Chronic Myeloid Leukemia (CML): A Retrospective Single-Center Experience

Onyee Chan, MD, Chetasi Talati, MD, Leidy Isenalumhe, MD, Michael Fradley, MD, Samantha Shams, MD, Javier Pinilla Ibarz, MD, Kendra L. Sweet, MD

Blood (2018) 132 (Supplement 1): 4259.

https://doi.org/10.1182/blood-2018-99-115660

Published: 2018

Journal Articles

Ponatinib efficacy and safety in Philadelphia chromosome–positive leukemia: final 5-year results of the phase 2 PACE trial

Blood (2018) 132 (4): 393–404.

https://doi.org/10.1182/blood-2016-09-739086

Published: 2018

Includes: Supplemental data

Journal Articles

Arterial Occlusive Events (AOEs) in the Phase 2 Ponatinib PACE Trial: 5-Year Update in Heavily Treated Patients (Pts) with Chronic-Phase Chronic Myeloid Leukemia (CP-CML)

Blood (2017) 130 (Supplement 1): 2896.

https://doi.org/10.1182/blood.V130.Suppl_1.2896.2896

Published: 2017

Journal Articles

A Real Life Evaluation of Efficacy and Safety of Ponatinib Therapy in CML Patients

Luigia Luciano, MD, Giorgina Specchia, MD, Bruno Martino, Vincenzo Accurso, MD, Marco Santoro, MD, Alessandra Malato, MD, Nicola Sgherza, Michele Pizzuti, MD, Fabio Stagno, MD PhD, Pellegrino Musto, MD, Attilio Guarini, MD, Fiorenza De Gregorio, MD, Santina Basile, MD, Fabrizio Pane, MD

Blood (2017) 130 (Supplement 1): 2905.

https://doi.org/10.1182/blood.V130.Suppl_1.2905.2905

Published: 2017

Journal Articles

Real-Life Experience with Ponatinib in Chronic Myeloid Leukemia (CML): A Multicenter Observational Study

Adi Shacham Abulafia, Pia Raanani, David Lavie, Yulia Volchek, Ron Ram, MD, Ilana Hellman, Liat Shargian, Anna Gourevietch, Evgeni Chubar, MD, Roy Ratzon, MD, Uri Rozovski

Blood (2017) 130 (Supplement 1): 5249.

https://doi.org/10.1182/blood.V130.Suppl_1.5249.5249

Published: 2017

Journal Articles

Efficacy and Safety of Ponatinib in Chronic Phase-Chronic Myeloid Leukemia (CP-CML) According to the Extent of Treatment with Prior Tyrosine Kinase Inhibitors (TKIs): Final (5-Year) Results of the PACE Study

Blood (2017) 130 (Supplement 1): 1617.

https://doi.org/10.1182/blood.V130.Suppl_1.1617.1617

Published: 2017

Journal Articles

Analysis of the Sub-Clonal Origins of Compound Mutations in Patients with Refractory Ph+ Malignancies Treated with Ponatinib

Justin R. Pritchard, PhD, Michael W. Schmitt, MD PhD, J. Graeme Hodgson, PhD, Stephanie Lustgarten, PhD, Shijie Tang, PhD, Lawrence A. Loeb, MD PhD, Jerald P. Radich, MD, Victor M. Rivera, PhD

Blood (2016) 128 (22): 1061.

https://doi.org/10.1182/blood.V128.22.1061.1061

Published: 2016

Journal Articles

Ponatinib Facilitates Treatment-Free Remission By Inducing Deep Molecular Responses

Brendan Wisniowski, MBBS, Sally Mapp, MBBS, PhD FRACP, FRCPA, Louise Knop, BSc (Hons), James Morton, MBBS, BSc(MD, FRACP, FRCPA, Paul Eliadis, FRACP,FRCPA,MBBS, Anthony K. Mills, MBBS, FRACP, FRCPA

Blood (2016) 128 (22): 5460.

https://doi.org/10.1182/blood.V128.22.5460.5460

Published: 2016

Journal Articles

Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients

Blood (2016) 127 (6): 703–712.

https://doi.org/10.1182/blood-2015-08-660977

Published: 2016

Includes: Supplemental data

Journal Articles

A Nationwide Observational Study of the Israeli Experience with Ponatinib Outside Clinical Trials in Chronic Myeloid Leukemia

Adi Shacham Abulafia, MD, Pia Raanani, MD, David Lavie, MD, Yulia Volchek, MD, Ron Ram, MD, Ilana Hellmann, MD, Liat Shargian, MD, Anna Gourevietch, MD, Evgeni Chubar, MD, Roy Ratzon, BSC, Uri Rozovski, MD

Blood (2015) 126 (23): 5155.

https://doi.org/10.1182/blood.V126.23.5155.5155

Published: 2015

Journal Articles

Evaluation of the Benefit/Risk Profile of Ponatinib in CP-CML Patients over Time: 4-Year Follow-up of the Phase 2 PACE Study

Blood (2015) 126 (23): 5142.

https://doi.org/10.1182/blood.V126.23.5142.5142

Published: 2015

Journal Articles

Daily Practice Experience in Ponatinib Treatment of Chronic Myeloid Leukemia (CML) Patients Resistant to Other Tyrosin Kynase Inhibitors (TKIs) in Argentina

Ana Inés Varela, MD, Romina Laura Penalba, Alicia Enrico, MD, Marta Catalan, Maria Veronica Ventriglia, Maria Josefina Freitas, Carolina Pavlovsky, MD, Susana Garbiero, PhD, Martin Beccasese, MD, Raquel Maria Nelida Bengio, MD, Catalina Abramovich, MD, Miguel A Pavlovsky, MD, Elena Beatriz Moiraghi, MD

Blood (2015) 126 (23): 5149.

https://doi.org/10.1182/blood.V126.23.5149.5149

Published: 2015

Journal Articles

Emergence of Sub-Clonal Drug Resistance Mutations during CML Therapy

Michael W. Schmitt, MD PhD, Justin R. Pritchard, PhD, Graeme Hodgson, PhD, Victor M. Rivera, PhD, Bella I. Aminov, Lan Beppu, Lawrence A. Loeb, MD PhD, Jerald P. Radich

Blood (2015) 126 (23): 478.

https://doi.org/10.1182/blood.V126.23.478.478

Published: 2015

Journal Articles

The Impact of Ponatinib Versus Allogeneic Stem Cell Transplant (SCT) on Outcomes in Patients with Chronic Myeloid Leukemia (CML) or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) with the T315I Mutation

Franck E. Nicolini, MD PhD, Grzegorz W. Basak, MD PhD, Dong-Wook Kim, MD PhD, Eduardo Olavarria, MD PhD, Javier Pinilla-Ibarz, MD PhD, Jane F. Apperley, MD, Timothy P. Hughes, MD, Dietger Niederwieser, MD, Michael J. Mauro, MD, Charles Chuah, MD PhD, Andreas Hochhaus, MD, Giovanni Martinelli, MD PhD, Maral DerSarkissian, PhD, Andrew Kageleiry, BS, Mo Yang, PhD, Hui Huang, MBA, PhD, Lisa J. McGarry, MPH, Hagop M. Kantarjian, MD, Jorge E. Cortes, MD

Blood (2015) 126 (23): 480.

https://doi.org/10.1182/blood.V126.23.480.480

Published: 2015

Journal Articles

Efficacy and Safety of Ponatinib in CP-CML Patients By Number of Prior Tyrosine Kinase Inhibitors: 4-Year Follow-up of the Phase 2 PACE Trial

Blood (2015) 126 (23): 4025.

https://doi.org/10.1182/blood.V126.23.4025.4025

Published: 2015

Journal Articles

Relationship of Line of Therapy to Efficacy for Ponatinib in 3rd-Line Versus 4th-Line Chronic-Phase Chronic Myeloid Leukemia (CML)

Moshe Yair Levy, MD, Lisa J. McGarry, MPH, Stephanie Lustgarten, PhD, Mo Yang, PhD, Frank G. Haluska, MD

Blood (2015) 126 (23): 1588.

https://doi.org/10.1182/blood.V126.23.1588.1588

Published: 2015

Journal Articles

Real-World Ponatinib Prescribing Patterns and Outcomes in US Patients

Michael J. Mauro, MD, Lisa J. McGarry, MPH, Mo Yang, PhD, Stephanie Lustgarten, PhD, Hui Huang, MBA, PhD

Blood (2015) 126 (23): 1591.

https://doi.org/10.1182/blood.V126.23.1591.1591

Published: 2015

Journal Articles

High-Resolution Analysis of the Relationship Between Dose and Molecular Response in CP-CML Patients Treated with Ponatinib or Imatinib

Justin R. Pritchard, Stephanie Lustgarten, Graeme Hodgson, Michele Baccarani, MD, Jorge E. Cortes, MD, Michael W. Deininger, Francois Guilhot, Andreas Hochhaus, MD, Timothy P. Hughes, Neil P. Shah, Moshe Talpaz, Tim Clackson, Frank G. Haluska, Ronald Knickerbocker, Victor M. Rivera

Blood (2014) 124 (21): 3153.

https://doi.org/10.1182/blood.V124.21.3153.3153

Published: 2014

NARROW

Ponatinib Treatment in CML and Ph+ ALL Patients: Real-Life Data from the Czech Registries

Preliminary Results of CML1214, a Survey on Ponatinib Compassionate Use in Italy By the Gimema CML Working Party

Outcomes and Side Effect Profile of Ponatinib in Treatment of Chronic Myeloid Leukemia (CML): A Retrospective Single-Center Experience

Ponatinib efficacy and safety in Philadelphia chromosome–positive leukemia: final 5-year results of the phase 2 PACE trial

Arterial Occlusive Events (AOEs) in the Phase 2 Ponatinib PACE Trial: 5-Year Update in Heavily Treated Patients (Pts) with Chronic-Phase Chronic Myeloid Leukemia (CP-CML)

A Real Life Evaluation of Efficacy and Safety of Ponatinib Therapy in CML Patients

Real-Life Experience with Ponatinib in Chronic Myeloid Leukemia (CML): A Multicenter Observational Study

Efficacy and Safety of Ponatinib in Chronic Phase-Chronic Myeloid Leukemia (CP-CML) According to the Extent of Treatment with Prior Tyrosine Kinase Inhibitors (TKIs): Final (5-Year) Results of the PACE Study

Analysis of the Sub-Clonal Origins of Compound Mutations in Patients with Refractory Ph+ Malignancies Treated with Ponatinib

Ponatinib Facilitates Treatment-Free Remission By Inducing Deep Molecular Responses

Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients

A Nationwide Observational Study of the Israeli Experience with Ponatinib Outside Clinical Trials in Chronic Myeloid Leukemia

Evaluation of the Benefit/Risk Profile of Ponatinib in CP-CML Patients over Time: 4-Year Follow-up of the Phase 2 PACE Study

Daily Practice Experience in Ponatinib Treatment of Chronic Myeloid Leukemia (CML) Patients Resistant to Other Tyrosin Kynase Inhibitors (TKIs) in Argentina

Emergence of Sub-Clonal Drug Resistance Mutations during CML Therapy

The Impact of Ponatinib Versus Allogeneic Stem Cell Transplant (SCT) on Outcomes in Patients with Chronic Myeloid Leukemia (CML) or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) with the T315I Mutation

Efficacy and Safety of Ponatinib in CP-CML Patients By Number of Prior Tyrosine Kinase Inhibitors: 4-Year Follow-up of the Phase 2 PACE Trial

Relationship of Line of Therapy to Efficacy for Ponatinib in 3rd-Line Versus 4th-Line Chronic-Phase Chronic Myeloid Leukemia (CML)

Real-World Ponatinib Prescribing Patterns and Outcomes in US Patients

High-Resolution Analysis of the Relationship Between Dose and Molecular Response in CP-CML Patients Treated with Ponatinib or Imatinib

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only